MetaCap

Liquidia Corporation (LQDA)

NASDAQ: LQDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

54.43-2.20 (-3.88%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LQDA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.05
52-week range
22.31 – 93.61
Day range
53.98 – 57.21
Volume / Avg
1.69M / 3.52M
Beta
—

52-week range

$22.31$93.61

LQDA stock today

Shares of Liquidia (LQDA) finished lower on Nov 20 at $54.43, a drop of 3.88% or $2.20 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.69M shares changing hands, about 48% of the average daily volume. At this level, LQDA sits in the middle of its 52-week range of $22.31 to $93.61: 41.9% below the high, set on Aug 11, 2026 and 144.0% above the low.

LQDA is up 57.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 87.0%. Liquidia has posted a net loss over the last twelve months (EPS of -$1.05), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Liquidia

Company profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Roger A. Jeffs Ph.D.
Headquarters
Morrisville, NC
Employees
216
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Liquidia generated $158.3 million in revenue, up 1031.2% from fiscal 2024. Liquidia reported a net loss of $68.9 million, compared with a loss of $128.3 million a year earlier. Operating margin was -32.5%.

Liquidia annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$158.32M$14.00M$17.49M$15.94M$12.85M
Growth+1031.18%-19.97%+9.75%+23.98%+1637.77%
Net income$-68.92M$-128.29M$-78.50M$-41.02M$-34.58M
EPS (diluted)$-0.80$-1.63$-1.21$-0.67$-0.70

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$66.13+21.50%

  • Strong buy 1
  • Buy 5
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $40.00High $87.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.04 vs $0.77
Surprise
-105.19%

LQDA news

All LQDA news

Liquidia peers

Health Care sector
LQDA peer companies
CompanyPrice% ChgMarket capCompare
ERASErasca Inc.13.61-4.29%$4.78Bvs LQDA
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs LQDA
DNTHDianthus Therapeutics Inc.84.55-0.33%$4.76Bvs LQDA
PTCTPTC Therapeutics Inc.56.42-3.27%$4.71Bvs LQDA
COGTCogent Biosciences Inc.26.72-3.69%$4.65Bvs LQDA
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs LQDA
TVTXTravere Therapeutics Inc.47.00-2.69%$4.51Bvs LQDA
IONSIonis Pharmaceuticals Inc.26.58-2.35%$4.43Bvs LQDA

Indexes, lists and sector

Liquidia stock FAQ

What is Liquidia's stock price today?

LQDA last traded at $54.43 as of Nov 20, 4:00 PM EST, down 3.88% on the day. Prices are delayed at least 15 minutes.

Who is Liquidia's CEO?

Dr. Roger A. Jeffs Ph.D. is the chief executive officer of Liquidia Corporation, which has about 216 employees.

What is the LQDA 52-week high?

The 52-week high for LQDA is $93.61 and the 52-week low is $22.31. The stock is currently 41.9% below its high.

Compare LQDA